0:00 - Introductions: Reconnecting with Katie Emerson at Expo West 2025 The episode opens with Mike and Ben welcoming Katie Emerson back to the podcast after roughly 18 months
Non-alcoholic fatty liver disease and nonalcoholic steatohepatitis NAFLD, particularly its inflammatory subtype NASH, is closely associated with obesity and T2DM [243]
A medication that achieves 24% weight loss and dramatically improves fatty liver disease could potentially prevent expensive complications down the road
Tesamorelin: The FDA-Approved Benchmark What sets tesamorelin apart Tesamorelin holds a unique position in the GH peptide landscape: it is the only GHRH analogue to receive FDA approval, granted in 2010 under the brand name Egrifta for the treatment of excess abdominal fat in HIV-infected adults with lipodystrophy a metabolic complication characterised by visceral fat accumulation and altered fat distribution
How do I maximize my results from VelaShape
To minimize treatment interruptions due to adverse reactions, subsequent Phase III clinical trials may adopt a more gradual dose-escalation strategy to reduce the incidence and severity of gastrointestinal discomfort and other adverse events, thereby enhancing patient tolerance and adherence to the medication